Rona Therapeutics, a Shanghai, China-based scientific stage platform firm which makes a speciality of nucleic acid drug analysis and improvement, raised $35M in Collection A+ funding.
The spherical was led by LongRiver Investments with participation from new and current international funding funds
The corporate intends to make use of the funds to progress metabolic siRNA pipeline packages into international improvement and increase extra-hepatic supply platform in CNS and past.
Led by CEO and Founder Ms. Stella SHI, Rona Therapeutics is a nucleic acid revolutionary drug platform firm, specializing within the therapy of metabolic illnesses and CNS degenerative illnesses. Rona is advancing a pipeline of siRNA packages generated from subsequent technology siRNA platform. The corporate’s first program RN0191, a best-in-class PCSK9 siRNA program, has accomplished Australia and China Ph1 scientific research and prepared for Ph2 scientific improvement for hypercholesterolemia. RN0361 is the corporate’s second program to enter clinic in 2024Q2 for hypertriglyceridemia. Rona can be advancing revolutionary pipeline at IND enabling stage for kidney illness, weight problems and cardiometabolic illnesses.
FinSMEs
19/07/2024
